These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
187 related articles for article (PubMed ID: 22872790)
1. Clinical utility of treprostinil and its overall place in the treatment of pulmonary arterial hypertension. Mirza S; Foley RJ Clin Med Insights Circ Respir Pulm Med; 2012; 6():41-50. PubMed ID: 22872790 [TBL] [Abstract][Full Text] [Related]
2. Inhaled treprostinil: a therapeutic review. Channick RN; Voswinckel R; Rubin LJ Drug Des Devel Ther; 2012; 6():19-28. PubMed ID: 22291467 [TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986 [TBL] [Abstract][Full Text] [Related]
8. Safety and tolerability of transition from inhaled treprostinil to oral selexipag in pulmonary arterial hypertension: Results from the TRANSIT-1 study. Frost A; Janmohamed M; Fritz JS; McConnell JW; Poch D; Fortin TA; Miller CE; Chin KM; Fisher M; Eggert M; McEvoy C; Benza RL; Farber HW; Kim NH; Pfister T; Shiraga Y; McLaughlin V J Heart Lung Transplant; 2019 Jan; 38(1):43-50. PubMed ID: 30391194 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial. Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827 [TBL] [Abstract][Full Text] [Related]
10. Prostanoids for pulmonary arterial hypertension. Galiè N; Manes A; Branzi A Am J Respir Med; 2003; 2(2):123-37. PubMed ID: 14720012 [TBL] [Abstract][Full Text] [Related]
11. Differential response to intravenous prostacyclin analog therapy in patients with pulmonary arterial hypertension. Walkey AJ; Fein D; Horbowicz KJ; Farber HW Pulm Pharmacol Ther; 2011 Aug; 24(4):421-5. PubMed ID: 21251994 [TBL] [Abstract][Full Text] [Related]
12. Pulmonary arterial hypertension: new insights into the optimal role of current and emerging prostacyclin therapies. Waxman AB; Zamanian RT Am J Cardiol; 2013 Mar; 111(5 Suppl):1A-16A; quiz 17A-19A. PubMed ID: 23414683 [TBL] [Abstract][Full Text] [Related]
13. Inhaled treprostinil for the treatment of pulmonary arterial hypertension. Poms A; Kingman M Crit Care Nurse; 2011 Dec; 31(6):e1-10. PubMed ID: 22135338 [TBL] [Abstract][Full Text] [Related]
14. Oral treprostinil for the treatment of pulmonary arterial hypertension in patients receiving background endothelin receptor antagonist and phosphodiesterase type 5 inhibitor therapy (the FREEDOM-C2 study): a randomized controlled trial. Tapson VF; Jing ZC; Xu KF; Pan L; Feldman J; Kiely DG; Kotlyar E; McSwain CS; Laliberte K; Arneson C; Rubin LJ; Chest; 2013 Sep; 144(3):952-958. PubMed ID: 23669822 [TBL] [Abstract][Full Text] [Related]
15. Extended-release oral treprostinil for the treatment of pulmonary arterial hypertension. Skoro-Sajer N; Lang I Expert Rev Cardiovasc Ther; 2014 Dec; 12(12):1391-9. PubMed ID: 25363827 [TBL] [Abstract][Full Text] [Related]